Back to Awarded Treatment Trials
Awarded Trial: 03T-457
Grant ID
03T-457
Illness
Bipolar Disorder
Primary Drug/Intervention
Riluzole
Primary Dosage
up to 200 mg/day
Secondary Drug Intervention
N/A
Secondary Dosage
N/A
Other Drug/Intervention
N/A
Other Dosage
N/A
Status
Completed
Investigator
Payne
Sample Size
94
Duration of Study Period for Each Subject
8 weeks
Outcome Measurements
MADRS, YMRS, HAM-D, CGI
Results
Ninety-four (94) patients with BP I or II, depressed phase, without psychotic features, were randomized to riluzole 200 mg/d or placebo for 8 weeks. Riluzole decreases the release of glutamate and has been used in the treatment of amyotrophic lateral sclerosis. Assessment was with YMRS, MADRS, and CGI. Both groups improved, with the placebo group doing somewhat better than the riluzole group. Thus, it is a clean negative study.
Publication
N/A
Link
N/A
PI Name
Jennifer Payne
Degree
MD
Center
Department of Psychiatry
Institution
The Johns Hopkins University
Address
600 N. Wolfe Street, Meyer 3-165
City or Town
Baltimore
State or Province
MD
Zip or Postal Code
21287
Country
USA
Email Address
jpayne5@jhmi.edu